Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? | Journal of Neural Transmission
Parkinson’s disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degeneration involves several neurotransmission systems, resulting in a heterogeneous disease characterized by motor and non-motor symptoms. PD causes progressive disability that responds only to symptomatic therapies. Future advances include neuroprotective strategies for use in at-risk populations before the clinical onset of disease, hence the continuing need to identify reliable biomarkers that can facilitate the clinical diagnosis of PD. In this evaluative review, we summarize information on potential diagnostic biomarkers for use in the clinical and preclinical stages of PD. Avoid common mistakes on your manuscript. Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease: the incidence rate is 8–18 per 100,000 person-years in prospective population-based studies and the prevalence increases with age, the main known risk factor (Lee and Gilbert
Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? Neurology and Preclinical Neurological Studies - Review Article Open access Published: 25 August 2018 Volume 125 , pages 1417–1432 ( 2018 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Journal of Neural Transmission Aims and scope Submit manuscript Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? Download PDF Abstract Parkinson’s disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degeneration involves sev
Explore this link on the map →related reading
- Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? | Journal of Neural Transmission | Springer Nature Linklink.springer.com
- Biomarkers for Parkinson’s Disease: How Good Are They? | Neuroscience Bulletin | Springer Nature Linklink.springer.com
- Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research | Metabolic Brain Disease | Springer Nature Linklink.springer.com
- Biomarkers for Parkinson’s Disease: How Good Are They? - PMCpmc.ncbi.nlm.nih.gov
- Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study - PMCpmc.ncbi.nlm.nih.gov
- Checking your browser - reCAPTCHApmc.ncbi.nlm.nih.gov
- Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand? - PubMedpubmed.ncbi.nlm.nih.gov
- Parkinson Disease - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status - PMCncbi.nlm.nih.gov
- Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis - Parkinson’s Disease - NCBI Bookshelfncbi.nlm.nih.gov
- Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson’s disease | npj Parkinson's Diseasenature.com
- Neurology® Journalsneurology.org